Efficacy and safety of adalimumab in the treatment of Rheumatoid Arthritis (RA) in real-life clinical practice: 1-year-results of the react study by Burmester, G, Wordsworth, P, Saez, I, Malaise, MG, Kary, S, Kupper, H

Remission and major clinical response in active rheumatoid arthritis (RA) patients after adalimumab (Humira (R)) treatment by Burmester, G, Wordsworth, P, McKenna, F, Farraccioli, G, Flipo, R, Kary, S, Kupper, H

Efficacy and safety of adalimumab (Humira (R)) in European clinical practice: The ReAct trial by Burmester, G, Wordsworth, P, Mariette, X, Saez, I, Bijlsma, J, Webber, D, Kupper, H

Predictors of good clinical response (BASDAI 50 or ASAS partial remission) in 1,250 patients treated with adalimumab (humira (R)) for active ankylosing spondylitis (AS) by Rudwaleit, M, Claudepierre, P, Wordsworth, P, Loza, E, Wong, R, Kron, M, Kary, S, Kupper, H

IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS), ADALIMUMAB IMPROVES INFLAMMATORY BOWEL DISEASE (IBD) AND PSORIASIS (Ps) AND PREVENTS ANTERIOR UVEITIS (AU) FLARES by Wordsworth, P, Rudwaleit, M, Claudepierre, P, Loza, E, Olivieri, I, Wong, R, Oezer, U, Kary, S, Kupper, H

Adalimumab (HUMIRA (R)) improves inflammatory bowel disease (IBD) and psoriasis (Ps) and prevents anterior uveitis (AU) flares in patients with Ankylosing spondylitis (AS) by Rudwaleit, M, Claudepierre, P, Loza, E, Wordsworth, P, Olivieri, I, Wong, R, Oezer, U, Kary, S, Kupper, H

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. by Rudwaleit, M, Claudepierre, P, Wordsworth, P, Cortina, E, Sieper, J, Kron, M, Carcereri-De-Prati, R, Kupper, H, Kary, S

Adalimumab is effective and well-tolerated in patients with ankylosing spondylitis (AS) in day-to-day clinical practice - Results from rhapsody by Wordsworth, P, Claudepierre, P, Loza, E, Olivieri, I, Keat, A, Mantika, I, Wong, R, Kron, M, Kupper, H, Rudwaleit, M

CLINICAL RESPONSE AND PARTIAL REMISSION SUSTAINED THROUGH 3 YEARS OF ADALIMUMAB TREATMENT IN THE ATLAS TRIAL by Wordsworth, P, van der Heijde, D, Dijkmans, B, Schiff, M, Kivitz, A, de Vlam, K, Ballal, S, Kupper, H, Wong, R, Sieper, J

Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-... by van der Heijde, D, Dijkmans, B, Schiff, M, Kivitz, A, de Vlam, K, Wordsworth, P, Ballal, S, Kupper, H, Wong, R, Sieper, J, Grp, A

Adalimumab sustains improvement in spinal mobility in as patients through 104 weeks - Results from atlas by Wordsworth, P, Dijkmans, B, van der Heijde, D, Davis, J, Schiff, M, Kivitz, A, Sieper, J, Mease, P, Kupper, H, Wong, R, Grp, A

Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS. by van der Heijde, D, Kivitz, A, Schiff, M, Sieper, J, Dijkmans, B, Braun, J, Dougados, M, Wordsworth, P, Wong, R, Kupper, H, Davis, J

Improvements in health related quality of life (HRQL) correlate positively with clinical reponses in ankylosing spondylitis (AS) patients - Results from ATLAS by Van der Heijde, D, Luo, M, Davis, J, Zeidler, H, Mease, P, Breban, M, Cantini, F, Westhovens, R, Wordsworth, P, Wong, R, Kupper, H, Revicki, D

Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis by Wouters C, McIlraith MJ, Ilowite N, Chalom E, Jones OY, Koné-Paut I, Higgins G, Gamir M, Reiff A, Lovell DJ, Ruperto N, Liu S, Kupper H, Giannini EH, Martini A